Details of the Drug

General Information of Drug (ID: DM0CVXA)

Drug Name

Mechlorethamine

Synonyms

Antimit; Carolysine; Caryolysin; Caryolysine; Chlorethazine; Chlormethine; Cloramin; Clormetina; Dichloren; Embechine; Embichin; MBA; Mebichloramine; Mechlorethanamine; Mechloroethamine; Mecloretamina; Mustargen; Mustine; Mutagen; Nitrogranulogen; Thyldiethylamine; Dichlor amine; Me chloroethamine; Mecloretamina [Italian]; Mustine note; Nitrogen mustard; HN2; T 1024; TL 146; Chloramine (the nitrogen mustard); Chlormethine (INN); Chlormethine [INN:BAN]; Chlormethinum [INN-Latin]; Clormetina [INN-Spanish]; ENT-25294; HN-2; IBS-L0033631; Mustargen (TN); N-Lost; N-Methyl lost; Stickstofflost (ebewe); T-1024; Bis(2-chloroethyl)methylamine; Bis(beta-chloroethyl) methylamine; Bis(beta-chloroethyl)methylamine; Di(2-chloroethyl)methylamine; Methylbis(2-chloroethyl)amine; Methylbis(beta-chloroethyl)amine; Methyldi(2-chloroethyl)amine; N-Methyl-lost; N-Methyl-lost [German]; Nitrogen mustard (HN-2); Mitoxine (*Hydrochloride*); N,N-Di(chloroethyl)methylamine; N-Methyl-bis-chloraethylamin; N-Methyl-bis-chloraethylamin [German]; Nitol (*Hydrochloride*); Stickstofflost (*Hydrochloride*); N,N-Bis(2-chloroethyl)methylamine; N-Methyl-bis(2-chloroethyl)amine; N-Methyl-bis(beta-chloroethyl)amine; Beta,beta'-Dichlorodiethyl-N-methylamine; N-Methyl-2,2'-dichlorodiethylamine; N,N-Bis(2-chloroethyl)-N-methylamine; 1,5-Dichloro-3-methyl-3-azapentane hydrochloride; 2,2'-Dichloro-N-me; 2,2'-Dichloro-N-methyldiethylamine; 2,2'-Dichlorodiethyl-methylamine; 2-Chloro-N-(2-chloroethyl)-N-methylethanamine

Indication

Disease Entry	ICD 11	Status	REF
T-cell lymphoma	2A90	Approved	[1]
Hodgkin lymphoma	2B30	Phase 3	[2], [1]

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

156.05

Topological Polar Surface Area (xlogp)

0.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 15 minutes [3]

Chemical Identifiers

Formula: C5H11Cl2N
IUPAC Name: 2-chloro-N-(2-chloroethyl)-N-methylethanamine
Canonical SMILES: CN(CCCl)CCCl
InChI: InChI=1S/C5H11Cl2N/c1-8(4-2-6)5-3-7/h2-5H2,1H3
InChIKey: HAWPXGHAZFHHAD-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4033
ChEBI ID: CHEBI:28925
CAS Number: 51-75-2
DrugBank ID: DB00888
TTD ID: D03SSE

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Intercalator	[4]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Mechlorethamine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Mechlorethamine and Roflumilast.	Asthma [CA23]	[15]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of Mechlorethamine due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Sparfloxacin	DMB4HCT	Minor	Decreased absorption of Mechlorethamine due to intestinal mucosa variation caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of Mechlorethamine due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Norfloxacin	DMIZ6W2	Minor	Decreased absorption of Mechlorethamine due to intestinal mucosa variation caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[16]
ABT-492	DMJFD2I	Minor	Decreased absorption of Mechlorethamine due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[16]
Levofloxacin	DMS60RB	Minor	Decreased absorption of Mechlorethamine due to intestinal mucosa variation caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Lomefloxacin	DMVRH9C	Minor	Decreased absorption of Mechlorethamine due to intestinal mucosa variation caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Mechlorethamine and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[17]
Penbutolol	DM4ES8F	Minor	Increased plasma concentration of Mechlorethamine and Penbutolol due to competitive binding of plasma proteins.	Hypertension [BA00-BA04]	[18]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Mechlorethamine and Denosumab.	Low bone mass disorder [FB83]	[19]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Mechlorethamine and Thalidomide.	Multiple myeloma [2A83]	[20]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Mechlorethamine and Tecfidera.	Multiple sclerosis [8A40]	[21]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Mechlorethamine and Siponimod.	Multiple sclerosis [8A40]	[22]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Mechlorethamine and Fingolimod.	Multiple sclerosis [8A40]	[23]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Mechlorethamine and Ocrelizumab.	Multiple sclerosis [8A40]	[24]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Mechlorethamine and Ozanimod.	Multiple sclerosis [8A40]	[15]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Mechlorethamine and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[25]
Gatifloxacin	DMSL679	Minor	Decreased absorption of Mechlorethamine due to intestinal mucosa variation caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[16]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Mechlorethamine and Canakinumab.	Rheumatoid arthritis [FA20]	[26]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Mechlorethamine and Rilonacept.	Rheumatoid arthritis [FA20]	[26]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Mechlorethamine and Golimumab.	Rheumatoid arthritis [FA20]	[27]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Mechlorethamine when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[28]
Azathioprine	DMMZSXQ	Moderate	Additive immunosuppressive effects by the combination of Mechlorethamine and Azathioprine.	Transplant rejection [NE84]	[22]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Mechlorethamine and Ganciclovir.	Virus infection [1A24-1D9Z]	[22]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Mechlorethamine and Valganciclovir.	Virus infection [1A24-1D9Z]	[22]
-----------


⏷ Show the Full List of 26 DDI Information of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7218).
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Proteomic analysis of DNA-protein cross-linking by antitumor nitrogen mustards. Chem Res Toxicol. 2009 Jun;22(6):1151-62.
5	Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9.
6	Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
7	31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.
8	Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
9	O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
10	Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
11	DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8.
12	Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86.
13	Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
14	Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8.
15	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
16	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
17	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
18	Aguirre C, Rodriguez-Sasiain JM, Calvo R "Decrease in penbutolol protein binding as a consequence of treatment with some alkylating agents." Cancer Chemother Pharmacol 34 (1994): 86-8. [PMID: 8174208]
19	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
20	Figg WD, Arlen P, Gulley J, et al. "A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer." Semin Oncol 28(4 Suppl 15) (2001): 62-6. [PMID: 11685731]
21	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
22	Cerner Multum, Inc. "Australian Product Information.".
23	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
24	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
25	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
26	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
27	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
28	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]